Actavis to buy Forest Labs for $25bn

Dublin-based firm Actavis, one of the world’s largest generic-drugs makers by market value, has agreed to buy Forest Laboratories for about $25bn (€18bn).

The acquisition will change Actavis’s mix of sales, provide the combined drugmaker with over $1bn in cost savings, and bring Forest’s branded products to more markets.

“Forest presented an extraordinarily unique opportunity to create a new kind of company,” said Paul Bisaro, Actavis’s CEO.